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Binding of antigen-presenting cells (APC) to T cells via ad-
hesion molecules is thought to deliver accessory signals that 
are required for efficient T -cell activation. To determine 
whether Langerhans ce lls (LC) express relevant adhesion 
molecules on their surfaces, we employed two-color immu-
nofluorescence. Human epidermal cell s (EC), Ficoll-
enriched for LC (> 10%), were incubated with monoclonal 
antibodies (MoAb) specific for the adhesion molecules 
COll a (LFA-la), C018 (LFA-1,8), or ICAM-1; staining 
was evaluated by fluorescence microscopy. After 12 h of cul-
ture only HLA-OR+cells (LC) expressed COlla, C018, and 
ICAM-1. As a test for the functiona l relevance of such adhe-
C lose communication of APC and T cell s via surface molecules is required for antigen (Ag) -specific acti-vation ofT cel ls. AI though the essential interaction occurs between Ag bound to MHC molecules [on antigen-presenting cell (APe)] and T -cell receptor 
complexes, interaction between accessory molecul es (including ad-
hesion molecules) on APC and l1gands on T cells also dehvers sig-
nals required for efficient T-cell activation [1 -6]. Expression of 
adhesion molecul es on epidermal cells may play an important role 111 
the pathogenesis of inflammatory skin disorders (7 ,8]. Although LC 
have been reported to express several adhesion molecules [9 - 15], 
no studies tested their functiona l role. In the present study, we 
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Abbrev iations: 
Ag: anti gen 
APC: anti gen-presentin g ce ll 
EC: epidermal cells 
ICAM-1: intercel lul ar adhes ion molecule-1 
LC: epidermal Langerhans ce ll 
LFA-1: lymphocy te function-associated antigen 
MECLR: mixed epidermal-cell leukocyte reaction 
MHC: majo r histocompatibil ity complex 
MoAb: monoclonal ant ibody 
PBML: periph eral blood mononucl ear leukocytes 
(>H]TdR: (methy l 3 H ]- thymidi ne 
sion molecule expression, we examined the capacity of the 
above MoAb to block LC stimulation of alloreactive T cells: 
EC were co-cultured with allogeneic peripheral blood mono-
nuclear leukocytes (PBML) for 5 din the presence or absence 
of MoAb; proliferation was measured by [3H]- thymidine 
uptake. MoAb against COlla, C018, or ICAM-1 reduced 
the all ostimulatory capacity of LC by > 70%; combinations 
of these MoAb reduced proliferation even more (90%). We 
conclude that interaction of adhesion molecules on LC with 
ligands on T cells is required for optimal allo-antigen-
dependent T -cell activation, perhaps by delivering accessory 
signals.] Invest D ermato/96:148-151, 1991 
confirm the presence ofiCAM-1, CD11a, and CD18 on human LC 
and demonstrate their expression to be required for the optimal 
allostimulation. 
MATERIALS AND METHODS 
Media and Chemicals RPMI 1640 (Gibco, Grand Island, NY) 
was supplemented with 10% heat-inactivated human serum 
(Gibco),. 25 mM N~2-hydroxyethylpiperazine-N'-2-ethanesul­
fomc aCid (HEPES) (Sigma Chemical Co., St. Louis, MO), 1 nM 
non-essential amino acids (Gibco), 2 mM L-glutamine (Gibco), 
1 i~M 2-merc~ptoethano] (Sigma) , and 1% penici llin-streptomycin 
(Gibco). Mimmal essential medium (MEM) (Gibco) was supple-
mented with 1.3 U /ml DNAse I (ICN Biomedicals, Inc., Costa 
Mesa , CA), 10% FBS, and 1% penicillin-streptomycin (Gibco). 
[3H]-TdR (6 .7 Ci/mM) was purchased from ICN Radiochemicals, 
Irvine, CA. 
Monoclonal Antibodies We used MoAb 25.3.1. (anti-COlla), 
BL 5 (anti-CD18), 84H10 (anti-ICAM-1) (all from AMAC, Inc., 
W estbrook, ME), L243 (anti-HLA-DR) (Becton Dickinson, Sun-
nyvale, CA), and MAS 054 (anti-HLA-DR) (Accurate, Westbury, 
NY). 
EC Suspensions EC suspensions from neonatal foreskin were 
prepared as described previously [ 16, 17]. Disaggregated EC were 
resuspended 111 supplemented RPMI and seeded into petri dishes 
(Costar, Cambndge, MA) at 20 X 106 cell s/dish. After 12 h at 
37oC in 5% C02 non-adherent cell s were harvested and subjected 
to density gradient centrifu gation (1.077 Histopaque Sigma). Cells 
from the 111terface were harvested , yielding a population that rou-
tinely contained more than 10% of HLA-DR+ cells (LC). Cell 
viability , estimated by trypan blue exclusion, ranged from 70 to 
90%. 
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Figure 1. Human LC ex press the adhes ion molecules CO lla, C D18, and ICAM-1. Epiderm~ ! cells enriched for LC were double stained with MoAb 
agai nst HLA-DR and adhes ion molecules. A- C, D - F, and G-H represent the same microscopic field (magnification X400) viewed with phase contrast 
(A, D), a Texas red excitator (B,E,G), or flu orescein excitator (C,F,H) . (A) EC phase contrast, (B) anti - HLA-DR, (C) anti-C D1 8. (D) phase contrast, (E) 
anti- HLA-DR, (F) anti-CD 11 a. (G) anti-HLA-DR, (H) anti-ICAM-1. In A -F, LC are marked by the arrow. These resul ts are representative of eight 
separate experiments using EC from different donors each time. 
Isolation of Peripheral Blood Mononuclear Leukocytes 
(PBML) PBML were enriched from heparinized peripheral 
blood obtained from normal human volunteers by density centrifu-
gation over 1.077 Histopaque (Sigma) . Viability of cells recovered 
fro m the interface was > 90%, as determined by trypan blue exclu-
siOn. 
Mixed Epidermal Cell Leukocyte Reaction (MECLR) The 
MECLR was performed as described [1 6,17]. For these initial ex-
periments we utilized PBML, because previous studies [ 16, 17] did 
not observe any differences in MoAb-blocking studies of the 
MECLR, whether PBML or purified T cell s were used as respon-
ders. After 5 d of incubation in round bottom microtiter plates at 
37 °C in 5% C0 2 , cultures were pul sed for an additional1 8 h w ith 
(3H]-TdR (1!tCi jwell) and then coll ected onto nitrocellulose filter 
paper using a MASH II ce ll harvester. Incorporated [3H]-TdR was 
determined by liquid scintillation spectroscopy. All cultures were 
carried out in triplicate and results were calculated as the mean 
cpm ± SEM. Data are expressed as delta cpm (mean cpm of co-cui-
cures containing both KC and PBML minus the sum of mean cpm 
for KC and PBML cultured separately). 
MoAb Blocking MoAb were added at the indicated concentra-
tions and remained in the co-cultures throughout the incubation 
period. In other experiments, EC or PBML alone were pretreated 
wi th MoAb (2 h, 4 °C) , washed extensively, and then co-cultured. 
Immunofluorescence Staining Adhesion molecules on LC 
were identified by two color immunofluorescence, using a five-step 
staining protocol: 1) MoAb against adh esion molecul es (mouse 
IgG t> see above); 2) biotin-conjugated F(ab1) 2 fragments of goat-
anti-mouse IgG (Accurate); 3) FITC-conjugated Streptavidin 
Uackson Immuno Research, W estgrove, PA); 4) anti - HLA-DR 
MoAb (rat l gG 2, absorbed against mouse, see above); and 5) T exas 
red-conjugated F(ab1) 2 fra gments of goat-anti-rat IgG (absorbed 
against human and mouse) (Caltag, San Francisco, CA). For con-
trols, primary antibodi es were replaced with irre levant MoAb of the 
same isotype. Staining was performed at 4 oc and eva luated by fluo-
rescence microscopy using a Leitz flu orescence microscope. EC 
from 10 different donors were examined; at least 100 HLA-DR+ 
cells were examined for each double stain. 
RESULTS 
Human LC Express the Adhesion Molecules CD11a, CD18, 
and ICAM-1 Human LC, cul tured fo r 12 h , were identified by 
their bri ght HLA-DR surface stain (Fi g 1 ). All these DR+ cells were 
also positive for CD11a, CD18, and ICAM-1 (Fig 1). 
CD11a, CD18, and ICAM-1 on LC Participate in the Activa-
tion of Alloreactive T Cells To ide_nti fy a functiona l role for 
CD 11a, CD 18, or ICAM-1 on LC, we tested their contribution to 
the allostimulatory capacity ofLC in the MECLR; in this assay, onl y 
LC are capable of presenting alloantigens toT cells (16 - 18]. When 
MoAb against ICAM-1 , CD 11 a, or CD18 were added, theMECLR 
was inhibited in a dose-dependent manner (Fig 2). MoAb against 
CD 18 exhibited the greatest inhibitory effect (75% at 10 ,ug/ ml) , 
followed by anti-CD18 (65%) and anti-ICAM-1 (58%). An irrele-
vant control MoAb of the same isotype had no effect, excluding 
non-specific blocking effects of mouse IgG 1• 
Combinations of MoAb Against CD11a, CD18, and ICAM-1 
Inhibits Further the Allostimulatory Capacity ofLC W hen 
added separately, MoAb against ICAM-1, CD 11a, or CD 18 had 
produced signifi ca nt, but onl y partial , reductions in responsiveness 
(Fi g 2) . W hen MoAb against C D11 a, CD 18, and ICAM-1 were 
added to the co-cultures simultaneously the various combinations 
led to MECLR inhibition (88%) approaching that achieved w ith 
anti-HLA-DR MoAb (94%) (Fig 3). 
Pre-Incubation of Either LC or PBML with MoAb Against 
CD11a, CD18, or ICAM-1 Inhibits Allostimulation by 
LC T o identify w hich molecule on wh ich cell contributed to the 
MECLR, EC or PBMC were pre-treated with MoAb prior to co-
culture (Table I) . Treatment of EC with anti - ICAM-1 resulted in 
greater inhibition than the corresponding treatment of PBML; in 
fact, treatment of EC alone produced MECLR inhibition equal to 
that fo ll owing treatment of both EC and PBML, strongly suggest-
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Figure 2. COlla, CD18, and ICAM-1 on LC participate in the a.ctivation 
of alloreactive T cells. MoAb were added to the MECLR at the md1cated 
concentrations. After 5 d at 37 ' C in 5% C02 , proliferation was determined 
by (JH)-TdR incorporation. All cultures were carried out in triplicate, and 
data are expressed as delta cpm ± SEM. Results arc representative for 10 
separate experiments, using different donors of EC and PBMC each time. 
ing that MoAb against IC~-1 inhibit the MEC~R by acting pri-
marily on .LC. Treatment of wher EC or PBML wtth etther CJ?11a 
or CD18 inhibited the MECLR to a suntlar extent; when etther 
MoAb was added to both EC and PBML, inhibition was increased, 
suggesting that the CDlla/CD18 complex (LFA-1), expressed on 
both LC and T cells, contributes to the MECLR response. 
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Figure 3. CombinatiOI:s of MoAb against COlla, CD18, and ICAM-1 
inhibit further the allostlmulatory capac1ty of LC. MoAb were added to the 
MECLR at 10 11gj ml (control MoAb at 30 pg/ ml). After 5 d at 37"C in 5% 
C02, proliferation was determined by [JH]-TdR incorporation. All cultures 
were carried out in triplicate and data arc expressed as delta cpm ± SEM. 
Results arc representative for three separate experiments using different 
donors of EC and PBMC each time. 
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Table I. Pre-Incubation of Either EC or PBML with MoAb 
Against ICAM-1 or LFA-1 Inhibits the Mixed Epidermal Cell-
Le!Jkocyte Reaction 
MoAb Against• EC 
ICAM-1 58.6 
COlla 69.2 
CD18 49.2 
migG, ctrl. -1.0 
Cells Pre-Treated• 
(% inhibition)1 
PBML 
30.4 
62.1 
62.0 
-1.0 
EC + PBML* 
55.1 
88.3 
88.4 
6.7 
• EC or PBML were selectively treated with MoAb (10 ,ug/ ml, 2 h. 4 ' C) and then 
washed extensively prior to coculture. 
b Data are expressed as% inhibition ofMECLR (without MoAb), and were compared 
to the inhibition achieved, when both LC and PBML were treated (*) . 
DISCUSSION 
We have observed human LC (following 12 h culture) to express 
ICAM-1 and LFA-1 (CD11 a/CD 18) molecules, confirming recent 
studies that described ICAM-1 and CD18 (common beta chain of 
LFA-1) expression on normal human LC [12-15]. Our data also 
support previous observations of COl la (alpha chai·n of LFA-1) 
expression on LC [9- 11], although it should be noted that other 
investigators have been unable to detect this molecule [12,13]. This 
discrepancy is likely due to differences in MoAb, isolation tech-
niques, or culture conditions. 
The role of adhesion molecules in the induction ofT-cell activa-
tion has been the focus of recent attention [1-6,19-20] . MoAb 
against COlla, CD18, or ICAM-1 have been shown to inhibit 
T-cell proliferation in response to several stimuli, including soluble 
Ag, allo Ag, or mitogens [1,3,20 - 23]. The present study tested the 
functional relevance of CD11a/GD18 and ICAM-1 on LC, and 
revealed that ICAM-1 expression on LC is required for efficient 
activation of alloreactive T cells in the MECLR. Moreover, we 
observed that the CD11a/CD18 complex (LFA-1) is expressed on 
both LC and T cells, and that its presence on each cell contributes to 
the MECLR. This latter observation is not without precedent; 
CD11a/CD18 on both APC and responder T cells have been 
shown previously to participate in the primary mixed leukocyte 
reaction (21] . 
We conclude that ICAM-1 and LFA-1 on LC provide important 
accessory signals that are required for the effective activation of 
alloreactive T cells. Their contribution to the capacity of LC to 
present nominal Ag is the focus of ongoing investigation. 
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